MedTrace Logo

Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19

NCT04706533 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3402

Last updated 2023-10-31

No results posted yet for this study

Summary

To better understand the role of inflammation in COVID-19, we established the Michigan Medicine COVID-19 Cohort (M2C2). M2C2 is a funded and ongoing cohort which has currently enrolled over 1500 adult patients (≥18 years) with severe COVID-19 admitted at the University of Michigan. The purpose of M2C2 is to define the in-hospital course of these patients and understand the role of inflammation as a determinant of organ injury and outcomes in COVID-19.

Conditions

Interventions

DIAGNOSTIC_TEST

Biomarkers of inflammation

Biomarkers were measured on blood samples collected within 48 hours of admission

Sponsors & Collaborators

Principal Investigators

  • Salim Hayek, MD · University of Michigan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-23
Primary Completion
2022-12-01
Completion
2022-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04706533 on ClinicalTrials.gov